FDA approves Pliaglis sNDA

The FDA has approved an sNDA for Pliaglis (lidocaine+tetracaine) 7%/7% Cream. This topical local anaesthetic cream uses Nuvo Research's proprietary phase-changing technology to form a pliable peel on the skin when exposed to air.

Pliaglis is indicated for use on intact skin in adults to provide local analgesia for superficial aesthetic procedures, such as dermal filler injection, pulsed dye laser therapy, facial laser resurfacing and laser-assisted tattoo removal. Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma.

This article is tagged to:
Sector: Medical Devices
Geography: United States

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.